Literature DB >> 626715

Gluten-free diet in dermatitis herpetiformis. II. Morphological and immunological findings in the skin and small intestine of 12 patients and matched controls.

T Reunala.   

Abstract

Twelve patients with dermatitis herpetiformis whose skin condition responded to a gluten-free diet (GFD) were re-examined after diet treatment. The findings were compared with those in matched patients on a normal diet. Jejunal histology revealed morphological improvement in every patient on a GFD whereas all patients on a normal diet continued to have villous atrophy. Intra-epithelial lymphocyte counts were normal in 8 patients on a GFD in contrast to one on a normal diet. Immunofluorescence examination of the jejunal mucosa revealed that the numbers of cells containing IgA and IgM were increased significantly in the normal diet group. The figures were lower in the GFD group but these also exceeded the values in the controls. IgA deposits were found in the uninvolved skin of every patient irrespective of the diet treatment, but the fluorescence seemed to be less intense in patients on a GFD. A clear difference was found in the occurrence of C3 deposits in the uninvolved skin. Three patients on a GFD had C3 deposits; two of these did not follow a strict diet. However C3 was found in 8 patients on a normal diet. Circulating dietary and auto-antibodies were found in two patients on a GFD and in 9 on a normal diet. Serum immunoglobulin (IgG, IgA, IgM) and complement (C3, C4) levels were within normal limits in both patient groups.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 626715     DOI: 10.1111/j.1365-2133.1978.tb07335.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  10 in total

1.  Increase of lymphocytes bearing the gamma/delta T cell receptor in the jejunum of patients with dermatitis herpetiformis.

Authors:  E Savilahti; T Reunala; M Mäki
Journal:  Gut       Date:  1992-02       Impact factor: 23.059

2.  Expression of interleukin-4 and interferon-gamma in the small bowel of patients with dermatitis herpetiformis and isolated gluten-sensitive enteropathy.

Authors:  A D Smith; B Bagheri; R D Streilein; R P Hall
Journal:  Dig Dis Sci       Date:  1999-10       Impact factor: 3.199

3.  Serum antibodies to wheat germ agglutinin and gluten in patients with dermatitis herpetiformis.

Authors:  L M Sollid; H Scott; J Kolberg; P Brandtzaeg
Journal:  Arch Dermatol Res       Date:  1986       Impact factor: 3.017

4.  Circulating IgA- and IgG-class antigliadin antibodies in dermatitis herpetiformis detected by enzyme-linked immunosorbent assay.

Authors:  E Vainio; K Kalimo; T Reunala; M Viander; T Palosuo
Journal:  Arch Dermatol Res       Date:  1983       Impact factor: 3.017

Review 5.  Dermatitis herpetiformis.

Authors:  R P Hall; T J Lawley; S I Katz
Journal:  Springer Semin Immunopathol       Date:  1981-06

6.  Jejunal mucosal morphometry in children with and without gut symptoms and in normal adults.

Authors:  F J Penna; I D Hill; D Kingston; K Robertson; G Slavin; M Shiner
Journal:  J Clin Pathol       Date:  1981-04       Impact factor: 3.411

7.  Failure to detect C1q binding immune complexes in dermatitis herpetiformis.

Authors:  H Pehamberger; J Smolen; J Menzel
Journal:  Arch Dermatol Res       Date:  1980       Impact factor: 3.017

8.  Celiac disease or dermatitis herpetiformis in three patients with porphyria.

Authors:  P Mustajoki; M Vuoristo; T Reunala
Journal:  Dig Dis Sci       Date:  1981-07       Impact factor: 3.199

9.  Dermatitis herpetiformis: jejunal findings and skin response to gluten free diet.

Authors:  T Reunala; I Kosnai; S Karpati; P Kuitunen; E Török; E Savilahti
Journal:  Arch Dis Child       Date:  1984-06       Impact factor: 3.791

10.  The Long-Term Safety and Quality of Life Effects of Oats in Dermatitis Herpetiformis.

Authors:  Anna Alakoski; Kaisa Hervonen; Eriika Mansikka; Timo Reunala; Katri Kaukinen; Laura Kivelä; Pilvi Laurikka; Heini Huhtala; Kalle Kurppa; Teea Salmi
Journal:  Nutrients       Date:  2020-04-11       Impact factor: 5.717

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.